Personalized Pain Management via Genetic Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid analgesics, such as morphine, pose a high risk of serious adverse effects like respiratory depression due to unpredictable patient responses, particularly in children undergoing tonsillectomy, necessitating a personalized approach to analgesia that minimizes adverse effects while maximizing pain relief.
Innovation Solution
Genetic variants are used to categorize patients into low and high-risk groups for opioid-induced adverse events, allowing for the selection of appropriate analgesics and dosage adjustments based on their genotype, employing a computer-implemented method and genetic testing to tailor analgesic medication selection and dosage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If morphine is used as the primary opioid analgesic for pain management, then significant analgesic strength is achieved, but the risk of serious adverse effects such as respiratory depression increases due to unpredictable inter-patient variations
Solution Approach 1:
The patent performs genotyping for CYP2D6 and OPRM1 variants before administering morphine to identify patients at high risk for respiratory depression. This preliminary genetic assessment allows clinicians to anticipate adverse responses and adjust dosing or select alternative analgesics before the harmful effect occurs, resolving the contradiction between providing strong analgesia and preventing unpredictable respiratory depression
Solution Approach 2:
The patent changes the dosing parameter of morphine based on genetic test results. For patients with high-risk genotypes (CYP2D6 ultra-rapid metabolizers or OPRM1 A118G GG genotype), the morphine dose is reduced by 50% or alternative analgesics are selected. This parameter adjustment maintains adequate pain relief while preventing the harmful respiratory depression that would occur with standard dosing in genetically susceptible patients
2Reliability
If genetic testing is performed to personalize analgesic selection, then adverse effects are minimized and pain relief is optimized, but the complexity of the treatment process increases
Solution Approach 1:
The patent segments the patient population into distinct genetic risk groups based on CYP2D6 and OPRM1 genotyping results. By dividing patients into high-risk and low-risk categories with clear genomic markers, the complex variability in opioid response is simplified into manageable groups that can be addressed with specific dosing protocols or alternative analgesic selections, making personalized medicine more clinically feasible
Solution Approach 2:
The patent introduces genetic testing as an intermediary step between pain assessment and analgesic administration. This intermediary genotyping process provides objective biological data that guides dosing decisions, replacing subjective clinical judgment with genetically-informed protocols. The intermediary test simplifies the decision-making process by providing clear high-risk/low-risk categorization that directly translates to dosing recommendations
Data Source
AI summary
The invention provides methods, kits and systems related to personalized pain management.